|
Sanofi-aventis enters into Antibody Agreements with Dyaxand "Phage Display Technology" |
|
|
|
12 Feb 2008 |
|
Sanofi-aventis and Dyax Corp. announced today that they have entered into agreements in which sanofi-aventis has been granted an exclusive worldwide license for the development and commercialization of its fully human monoclonal antibody DX-2240
|
